title: Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach.
abstract: The Alzheimer's disease (AD) Cognitive Behavior Section (ADAS-Cog) is the most commonly used cognitive test in clinical trials of AD. Recent trials have focused on people earlier in the course of disease; however, there are concerns about using the ADAS-Cog at this crucial stage. Using data from the Alzheimer's disease Neuroimaging Initiative study, we used a range of traditional psychometric tests to evaluate those concerns. This issue of Alzheimer's & Dementia includes two articles that evaluate the ADAS-Cog. These articles report evaluations using two psychometric approaches: traditional methods and new methods. In this review, we provide accompanying background information to this program of research.
authors: Pfizer Inc, New York, NY, USA.
authors: Holly B
authors: HB
authors: Posner
authors: Stefan
authors: S
authors: Cano
authors: Maria C
authors: MC
authors: Carrillo
authors: Ola
authors: O
authors: Selnes
authors: Yaakov
authors: Y
authors: Stern
authors: Ronald G
authors: RG
authors: Thomas
authors: John
authors: J
authors: Zajicek
authors: Jeremy
authors: J
authors: Hobart
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis* / Q000523:psychology*; D002986:Clinical Trials as Topic; D006801:Humans; D009483:Neuropsychological Tests; D011594:Psychometrics / Q000379:methods*; D012107:Research Design